It has been reported that circulating PCSK9 levels increase with the severity of hepatic fat accumulation in patients at risk of NASH and PCSK9 mRNA levels in liver have been linked with steatosis severity (Ruscica et al, 2016). Here, PCSK9 is linked to metabolic dysfunction-associated steatohepatitis.